Last reviewed · How we verify
Negative Control
A negative control is an inactive or placebo substance used in clinical trials to establish baseline effects and validate that observed outcomes are due to the active drug rather than other factors.
At a glance
| Generic name | Negative Control |
|---|---|
| Also known as | 0.9% aqueous NaCl |
| Sponsor | UNION therapeutics |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Negative controls serve as comparators in pharmaceutical research to distinguish genuine drug efficacy from placebo effects, natural disease progression, or bias. They help establish the causal relationship between a drug's mechanism and its therapeutic effects by providing a reference point against which the active treatment can be measured.
Approved indications
Common side effects
Key clinical trials
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo.
- SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid (NA)
- The Effects of Mindfulness-based Cognitive Therapy in People With Parkinson's Disease (NA)
- A Clinical Study Assessing the Maximum Maxillary Bite Force When Using Three Denture Adhesives Compared to Using No-Adhesive (NA)
- Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia (NA)
- Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |